tesarobio.comAgreement to acquire TESARO | GSK

Company Back to main Company Company Purpose, strategy and culture Outstanding people Company Outstanding people Working together My GSK story Innovating together 2022 Innovating together 2021 GSK at a glance History and heritage Board of directors and leadership team Board information Governance Company Governance Committees Shareholders Sarbanes-Oxley Act 2002 Compliance Policy positions Codes, standards and reports FEATURED SECTION Our purpose, strategy and culture FEATURED SECTION Outstanding peopleInnovation Back to main Innovation Innovation Research and development approach Pipeline Therapeutic areas Innovation Therapeutic areas Infectious diseases HIV Respiratory/immunology Oncology Technologies Clinical trials at GSK Innovation Clinical trials at GSK Provision of unlicensed medicines for unmet medical needs Data transparency Diversity in clinical trials Partnering with GSK Innovation Partnering with GSK Supported studies R&D locations SPOTLIGHT ON Behind the science magazine Featured section Partnering with GSKProducts Back to main Products Products Our product areas Products A-Z SPOTLIGHT ON Innovation FEATURED WEBSITE GSKPro for healthcare professionalsResponsibility Back to main Responsibility Responsibility Access Global health and health security Responsibility Global health and health security Global health Health security Using our science for global health Improving access to healthcare Environment Responsibility Environment Climate Freshwater Land Oceans Atmosphere Materials and waste Diversity, equity and inclusion Ethical standards Responsibility Ethical standards Working with third parties Public policy and patient advocacy Human rights Use of animals Engaging with healthcare professionals Product governance Charitable Investments ESG resources Responsibility ESG resources ESG reports archive FEATURED SECTION Diversity equity and inclusion SPOTLIGHT ON Our policy positionsInvestors Back to main Investors Investors Why invest in GSK? Quarterly results Financial reports Investors Financial reports Annual Report 2023 Corporate reports archive Environmental, social and governance Speeches and presentations Science publications Events calendar Dividend and share price Investors Dividend and share price GSK share price Share price calculators (GBp/USD) Dividend calculators (GBp/USD) Dividend calendar Analyst consensus Stock exchange announcements Investors Stock exchange announcements London (RNS) London (RNS) inside information New York (SEC) Sign up for announcements Shareholder information Investors Shareholder information Manage your shares Annual General Meeting General Meeting Annual Governance Meeting Corporate sponsored nominee service Our ADR programme Asset reunification - ProSearch Share scam alert Privacy notice for ordinary shareholders FAQs Corporate actions Investors Corporate actions Consumer Healthcare Demerger Consumer Healthcare Joint Venture Agreement to acquire TESARO Debt investors Feedback Investor contacts SPOTLIGHT ON Press releases SPOTLIGHT ON Our pipelineMedia Back to main Media Media Press releases Media contacts Conferences Media library Our response to the situation in Ukraine Our response to the crisis in Israel and Gaza Our social media RSS feeds FEATURED SECTION Behind the science magazine SPOTLIGHT ON ConferencesCareers Back to main Careers Careers Search jobs Featured careers Careers Featured careers A career in Data Life at GSK Careers Life at GSK What’s your angle? Experienced professionals Careers Experienced professionals Business Operations Engineering at GSK Manufacturing and supply Marketing and sales Research and development Experienced professionals Research and development Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS) Genomic sciences Technology Early talent Careers Early talent Kickstart your career Apprentice programmes Work experience, placements and internships Future leaders graduate programme Early talent Future leaders graduate programme Business operations Engineering Manufacturing Operations, Quality & Supply Chain Marketing and sales Research and development Technology Manufacturing Sciences & Technology Post graduate opportunities Veterans Our global and regional hubs How we hire Careers How we hire Frequently asked questions Fraudulent internet recruitment activities FEATURED SECTION Outstanding people FEATURED SECTION Diversity equity and inclusionHealthcare professionals Healthcare professionals Contact us Contact us Home Investors Corporate actions Agreement to acquire TESARO Agreement to acquire TESARO On 3 December 2018 we announced our agreement to acquire TESARO, an oncology-focused company based in the US for approximately $5.1bn. The proposed transaction will significantly strengthen our pharmaceutical business, accelerating the build of our pipeline and commercial capability in oncology. View press release Investor call slide (PDF - 439 KB) Investor call transcript (PDF - 316 KB) Transformative potential from PARPs Our strong belief is that PARP inhibitors are important medicines that have been under appreciated in terms of the impact they can have on cancer patients. PARP inhibitors have transformed the treatment of ovarian cancer and offer significant opportunities for use in the treatment of multiple cancer types. PARP inhibitors may slow the return or progress of cancer by preventing cancer cells from repairing damaged DNA in cells PARP inhibitors have transformed the treatment of ovarian cancer, particularly those with genetic mutations such as BRCA PARPs are currently used in second line maintenance therapy in ovarian cancer and show potential to help 2-3 times as many patients in a first line maintenance setting You might also like Press releases Keep up to date with our latest new announcements Research and development approach Our R&D focuses on the science of the immune system and advanced technologies. Life at GSK We take on some of the biggest healthcare challenges in the world, improving hundreds of millions of lives in the process Continue to Debt investors GSK This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our location selector. © 2001-2024 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.Modern Slavery Act statement 2023 (PDF - 139.1KB) GSK websites Locations selector Social media directory GSKPro for healthcare professionals GSK study register Supplier website ViiV Healthcare Quick links Behind the science magazine Company Innovation Products Responsibility Investors Media Careers Get in touch Partnerships Report a possible side effect GSK Speak up Follow us on: facebook twitter youtube linkedin instagram rss Accessibility Terms of use Cookie policy Privacy notice...